UNSPSC 51121900: Drugs used for congestive heart failure

This classification denotes drugs that treat a heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. heart failure can be caused by structural defects, functional abnormalities (ventricular dysfunction), or a sudden overload beyond its capacity. chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as myocardial infarction.

UNSPSC 51121900 Drugs used for congestive heart failure is a Class code under which state and local governments procure cardiac and emergency pharmaceuticals—including beta-blockers, vasodilators, adenosine, and epinephrine formulations—for use by fire rescue services, health agencies, and hospital systems. Recent solicitations show state and local buyers sourcing specific formulations in bulk quantities with firm pricing, extended shelf-life requirements, and compliance with FDA, cGMP, and OSHA standards. The issuing-body mix includes fire and rescue departments (Tampa Fire Rescue), state health agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance). The code also supports broader pharmaceutical supply agreements that encompass congestive heart failure drugs alongside other multi-source generics and OTC products distributed through authorized wholesalers.

Activity concentrates in Florida, Texas, and Minnesota with cooperative purchasing vehicles extending reach across multiple states and participating jurisdictions. Tampa's Purchasing Department solicited Advanced Life Support Medications (Bid No. 26-P-00188) as an IFB with a due date of April 8, 2026, requesting 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials with a nine-month minimum expiration and one-year contract term; the estimated value was $40,000.00 and included a 5 percent Small Local Business Enterprise bid discount. The Texas Health and Human Services Commission issued RFI No. HHS0017013 (response deadline April 3, 2026) to evaluate vendor capacity for direct-to-manufacturer prescription programs and future state pharmacy benefit contracting. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, posted an RFP (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be stocked through authorized wholesalers with July 1, 2026 effective dates; evaluation weighted price competitiveness at 75 percent and required compliance with cGMP, DSCSA, and FDA standards, with a 3 percent administrative fee and performance penalties ranging from $200 to $1,500 per violation.